- Home
- ANTX
as 02-04-2025 2:30pm EST
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 37.6M | IPO Year: | 2022 |
| Target Price: | $3.50 | AVG Volume (30 days): | 110.0K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $21.40 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Day Lucy | ANTX | Chief Financial Officer | Jan 3 '25 | Sell | $1.34 | 2,957 | $3,965.34 | 32,670 | |
| Chanda Sanjay | ANTX | Chief Development Officer | Jan 3 '25 | Sell | $1.34 | 2,957 | $3,965.34 | 29,824 | |
| Eizen Joshua M | ANTX | See Remarks | Jan 3 '25 | Sell | $1.34 | 9,663 | $12,958.08 | 116,672 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Jan 3 '25 | Sell | $1.34 | 2,029 | $2,720.89 | 33,313 | |
| Readnour Robin Shane | ANTX | Director | Dec 6 '24 | Buy | $1.46 | 60,000 | $86,708.01 | 652,573 | |
| Zakrzewski Joseph S | ANTX | Director | Nov 27 '24 | Buy | $1.40 | 2,000 | $2,800.00 | 125,199 | |
| Readnour Robin Shane | ANTX | Director | Nov 26 '24 | Buy | $1.41 | 75,000 | $105,685.00 | 652,573 | |
| Readnour Robin Shane | ANTX | Director | Nov 19 '24 | Buy | $1.10 | 200,000 | $213,127.50 | 652,573 | |
| Easom Eric | ANTX | Chief Executive Officer | Nov 18 '24 | Buy | $1.00 | 50,000 | $49,970.00 | 1,065,766 | |
| Zakrzewski Joseph S | ANTX | Director | Nov 18 '24 | Buy | $1.00 | 25,000 | $25,046.00 | 125,199 |
Latest AN2 Therapeutics Inc. News
ANTX Breaking Stock News: Dive into ANTX Ticker-Specific Updates for Smart Investing
Business Wire
7 days ago
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Simply Wall St.
17 days ago
Favourable Signals For AN2 Therapeutics: Numerous Insiders Acquired Stock
Simply Wall St.
2 months ago
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor
Business Wire
3 months ago
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Business Wire
3 months ago
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
Business Wire
4 months ago
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
Business Wire
5 months ago
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Zacks
6 months ago
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
Compare ANTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.